Table 1.
Patient characteristics (all sample).
| Parameter | Category | P n (%) (n = 706) |
P + CHT n (%) (n = 87) |
p-value for difference between groups (test method) |
|---|---|---|---|---|
| Sex | Male | 427 (60.5) | 58 (66.7) | 0.2641(Chi-squared) |
| Female | 279 (39.5 | 29 (33.3) | ||
| ECOG PS | 0 | 47 (6.7) | 22 (25.3) | 0.0004(Mann-Whitney U) |
| 1 | 641 (90.9) | 58 (66.7) | ||
| 2 | 17 (2.4) | 7 (8.0) | ||
| Unknown* | 1 | 0 | ||
| Smoking | Smoker | 204 (57.1) | 33 (40.7) | 0.0238(Fisher) |
| Exsmoker | 121 (33.9) | 39 (48.1) | ||
| Never smoker | 32 (9.0) | 9 (11.1) | ||
| Unknown* | 349 | 6 | ||
| Stage | IIIA | 2 (0.3) | 1 (1.1) | <0.0001 (Mann-Whitney U) |
| IIIB | 3 (0.4) | 2 (2.3) | ||
| IIIC | 3 (0.4) | 0 (0.0) | ||
| IVA | 323 (45.8) | 17 (19.6) | ||
| IVB | 309 (43.8) | 66 (75.9) | ||
| IV (without specification)** | 66 (9.3) | 1 (1.1) | ||
| Histology | Adenocarcinoma | 413 (58.5) | 68 (78.2) | 0.0003(Chi-squared) |
| Sqamous carcinoma | 244 (34.6) | 14 (16.1) | ||
| Adenosqamous carcinoma** | 8 (1.1) | 2 (2.3) | ||
| Large cell carcinoma** | 4 (0.6) | 0 (0.0) | ||
| NOS** | 37 (5.2) | 3 (3.4) | ||
| PD-L1 Expression | < 80% | 305 (43.3) | 48 (56.5) | 0.0207(Chi-squared) |
| ≥ 80% | 400 (56.7) | 37 (43.5) | ||
| Unknown* | 1 | 2 |
* - Category not included in the percentage calculation and significance test
** - Category not included in the significance test
ECOG PS = Eastern Cooperative Oncology Group performance status; NOS = not otherwise specified; P = pembrolizumab; P + CHT = pembrolizumab + chemotherapy